Studies have shown that PD-L1 inhibitors and PD-1 inhibitors are effective in the first-line treatment of ES-SCLC (Horn et al. 2018; Liu et al. 2019; Paz-Ares et al. 2018; Leal et al. 2020). The gene discussed is CD274; the disease is small cell lung carcinoma.